Covered recipient · General Payments record
ADAM BRUFSKY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$328,723.59
226 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $138,736.00 | 34 |
| Consulting Fee | $128,900.39 | 71 |
| Travel and Lodging | $50,234.31 | 59 |
| Honoraria | $6,448.00 | 4 |
| Food and Beverage | $4,054.89 | 57 |
| Grant | $350.00 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $120,720.13 | 64 |
| PFIZER INC. | $87,228.82 | 43 |
| Myriad Genetic Laboratories, Inc. | $65,287.52 | 54 |
| AstraZeneca Pharmaceuticals LP | $13,333.84 | 17 |
| AstraZeneca UK Limited | $9,777.50 | 6 |
| GE HEALTHCARE | $8,081.36 | 11 |
| Stemline Therapeutics Inc. | $6,089.55 | 5 |
| PUMA BIOTECHNOLOGY, INC. | $4,796.84 | 7 |
| Eli Lilly and Company | $4,200.00 | 3 |
| Lilly USA, LLC | $4,150.54 | 4 |
| Genentech, Inc. | $2,205.52 | 2 |
| Genentech USA, Inc. | $2,203.46 | 2 |
| Novartis Pharmaceuticals Corporation | $257.03 | 2 |
| Tempus AI, Inc | $138.04 | 2 |
| Menarini Silicon Biosystems, Inc. | $129.16 | 1 |
| Exelixis Inc. | $113.10 | 2 |
| R-Pharm US LLC | $11.18 | 1 |
Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ADAM BRUFSKY
NPI 1518939537 · CMS profile ID 23688
PITTSBURGH, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1518939537?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ADAM BRUFSKY, NPI 1518939537, CMS profile ID 23688. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518939537?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). ADAM BRUFSKY, NPI 1518939537, CMS profile ID 23688. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518939537?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- ADAM BRUFSKY, NPI 1518939537, CMS profile ID 23688, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1518939537?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
226 matching records · $328,723.59 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 226.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Myriad Genetic Laboratories, Inc. | $6,300.00 | 09/24/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152528422 | CMS |
| Myriad Genetic Laboratories, Inc. | $2,100.00 | 09/24/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152528424 | CMS |
| Stemline Therapeutics Inc. | $1,170.00 | 09/23/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1142957672 | CMS |
| Myriad Genetic Laboratories, Inc. | $700.00 | 09/17/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152528418 | CMS |
| PFIZER INC. | $82.11 | 09/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131993019 | CMS |
| Genentech, Inc. | $55.52 | 09/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132972321 | CMS |
| Genentech, Inc. | $2,150.00 | 09/16/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132972323 | CMS |
| Stemline Therapeutics Inc. | $114.55 | 09/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1142957670 | CMS |
| PFIZER INC. | $203.78 | 09/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131597874 | CMS |
| PFIZER INC. | $369.00 | 09/06/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131598757 | CMS |
| AstraZeneca Pharmaceuticals LP | $95.85 | 09/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110533316 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.97 | 09/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110533008 | CMS |
| AstraZeneca Pharmaceuticals LP | $86.40 | 09/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110543045 | CMS |
| PFIZER INC. | $5,000.00 | 09/04/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131478351 | CMS |
| AstraZeneca UK Limited | $665.00 | 09/02/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110545067 | CMS |
| Myriad Genetic Laboratories, Inc. | $700.00 | 08/26/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152528416 | CMS |
| PFIZER INC. | $6,125.00 | 08/21/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131940597 | CMS |
| PFIZER INC. | $644.54 | 08/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131991237 | CMS |
| Myriad Genetic Laboratories, Inc. | $513.45 | 07/31/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152528414 | CMS |
| R-Pharm US LLC | $11.18 | 07/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1073225610 | CMS |
| Myriad Genetic Laboratories, Inc. | $700.00 | 07/28/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152528412 | CMS |
| Myriad Genetic Laboratories, Inc. | $1,400.00 | 07/24/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152528410 | CMS |
| PFIZER INC. | $420.50 | 07/19/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132036706 | CMS |
| PFIZER INC. | $346.61 | 07/19/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132036708 | CMS |
| GE HEALTHCARE | $1,869.00 | 07/17/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144685222 | CMS |
| GE HEALTHCARE | $1,558.00 | 07/17/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144685224 | CMS |
| Lilly USA, LLC | $1,050.00 | 07/10/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136002789 | CMS |
| Tempus AI, Inc | $125.04 | 07/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150161717 | CMS |
| Gilead Sciences, Inc. | $83.37 | 07/08/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133861604 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,995.00 | 07/01/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110541293 | CMS |
| Gilead Sciences, Inc. | $6,720.00 | 06/25/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133603238 | CMS |
| Myriad Genetic Laboratories, Inc. | $1,400.00 | 06/21/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152528408 | CMS |
| AstraZeneca UK Limited | $665.00 | 06/19/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110552580 | CMS |
| Gilead Sciences, Inc. | $110.77 | 06/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133735209 | CMS |
| Gilead Sciences, Inc. | $170.53 | 06/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133861598 | CMS |
| Gilead Sciences, Inc. | $251.77 | 06/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133861600 | CMS |
| Gilead Sciences, Inc. | $480.02 | 06/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133861602 | CMS |
| PFIZER INC. | $5,000.00 | 06/17/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131482601 | CMS |
| PFIZER INC. | $5,000.00 | 06/17/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131483562 | CMS |
| GE HEALTHCARE | $593.77 | 06/13/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144680593 | CMS |
| GE HEALTHCARE | $165.33 | 06/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144682814 | CMS |
| GE HEALTHCARE | $5.76 | 06/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144683102 | CMS |
| PFIZER INC. | $3,786.00 | 06/12/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131528392 | CMS |
| GE HEALTHCARE | $312.00 | 06/05/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144679988 | CMS |
| GE HEALTHCARE | $1,869.00 | 06/05/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144687554 | CMS |
| GE HEALTHCARE | $935.00 | 06/05/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144687556 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,995.00 | 06/03/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110533724 | CMS |
| AstraZeneca Pharmaceuticals LP | $84.86 | 06/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110552532 | CMS |
| Gilead Sciences, Inc. | $730.00 | 06/03/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133598543 | CMS |
| Myriad Genetic Laboratories, Inc. | $700.00 | 06/03/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152528406 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $22,628.53 | 17 |
| PY2025 | Principal investigator | $226,860.66 | 36 |
| PY2024 | Recipient | $18,222.75 | 10 |
| PY2024 | Principal investigator | $619,403.76 | 61 |
| PY2023 | Recipient | $17,617.52 | 14 |
| PY2023 | Principal investigator | $617,311.34 | 66 |
| PY2022 | Recipient | $18,110.00 | 11 |
| PY2022 | Principal investigator | $798,026.53 | 70 |
| PY2021 | Recipient | $18,822.84 | 15 |
| PY2021 | Principal investigator | $978,981.08 | 90 |
| PY2020 | Recipient | $23,428.85 | 19 |
| PY2020 | Principal investigator | $671,312.69 | 76 |
| PY2019 | Recipient | $14,051.00 | 2 |
| PY2019 | Principal investigator | $819,152.37 | 92 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
53 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,529.76 | 12/31/2025 | Non-covered Recipient Entity Magee Women's Hospital | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC | No dispute reported | 06/30/2026 | 1232925791 |
| Principal investigator 1 | Genentech, Inc. | $3,800.00 | 12/26/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH CANCER INSTITUTE CANCER SERVICES | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211678953 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $540.00 | 12/15/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH CANCER INSTITUTE | ALI-1201 | No dispute reported | 06/30/2026 | 1251753700 |
| Recipient | F. Hoffmann-La Roche AG | $503.68 | 12/12/2025 | Covered Recipient Physician | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211534171 |
| Recipient | F. Hoffmann-La Roche AG | $292.89 | 12/12/2025 | Covered Recipient Physician | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211534174 |
| Principal investigator 1 | Genentech, Inc. | $747.00 | 12/11/2025 | Non-covered Recipient Entity UPMC OSPARS | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211679809 |
| Principal investigator 1 | Genentech, Inc. | $4,462.00 | 11/26/2025 | Non-covered Recipient Entity UPMC OSPARS | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211679811 |
| Recipient | PFIZER INC. | $3,200.00 | 11/24/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228810901 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $84.50 | 11/17/2025 | Non-covered Recipient Entity UPMC Hillman Cancer Center | DS8201-A-U301 | No dispute reported | 06/30/2026 | 1223386768 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,782.01 | 11/07/2025 | Non-covered Recipient Entity UPMC Hillman Cancer Center | DS8201-A-U201 | No dispute reported | 06/30/2026 | 1223386766 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $325.56 | 11/03/2025 | Non-covered Recipient Entity Edward Hospital | DS8201-A-U305 | No dispute reported | 06/30/2026 | 1244555156 |
| Principal investigator 1 | Genentech, Inc. | $6,840.00 | 10/21/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH CANCER INSTITUTE CANCER SERVICES | Chemo trastuzumab vs chemo trastuzumab pertuzumab | No dispute reported | 06/30/2026 | 1211678905 |
| Recipient | F. Hoffmann-La Roche AG | $1,225.57 | 10/18/2025 | Covered Recipient Physician | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211534168 |
| Recipient | Novartis Pharmaceuticals Corporation | $665.08 | 10/10/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190291581 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $32,082.50 | 10/09/2025 | Non-covered Recipient Entity University Of Pittsburgh | Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced and unresectable or metas | No dispute reported | 06/30/2026 | 1235992457 |
| Principal investigator 1 | Genentech, Inc. | $4,587.00 | 09/25/2025 | Non-covered Recipient Entity UPMC OSPARS | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211679807 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $30,867.50 | 07/31/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH CANCER INSTITUTE | ALI-1201 | No dispute reported | 06/30/2026 | 1251753698 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $30,530.00 | 07/25/2025 | Covered Recipient Teaching Hospital Upmc - Presbyterian Shadyside | Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. | No dispute reported | 06/30/2026 | 1185537425 |
| Recipient | PFIZER INC. | $330.00 | 07/08/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228810919 |
| Recipient | PFIZER INC. | $330.00 | 07/07/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228810895 |
| Recipient | PFIZER INC. | $3,200.00 | 06/24/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228838536 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $976.68 | 06/20/2025 | Non-covered Recipient Entity UPMC Hillman Cancer Center | DS8201-A-U305 | No dispute reported | 06/30/2026 | 1223386764 |
| Principal investigator 1 | Genentech, Inc. | $4,821.25 | 06/09/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH CANCER INSTITUTE CANCER SERVICES | Chemo trastuzumab vs chemo trastuzumab pertuzumab | No dispute reported | 06/30/2026 | 1211678903 |
| Recipient | PFIZER INC. | $3,200.00 | 06/04/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228838125 |
| Recipient | PFIZER INC. | $3,200.00 | 06/04/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228838134 |
| Principal investigator 1 | Genentech, Inc. | $747.00 | 05/29/2025 | Non-covered Recipient Entity UPMC OSPARS | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211679801 |
| Principal investigator 1 | Genentech, Inc. | $2,047.00 | 05/15/2025 | Non-covered Recipient Entity UPMC OSPARS | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211679799 |
| Recipient | PFIZER INC. | $940.00 | 05/15/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228838424 |
| Recipient | PFIZER INC. | $330.00 | 05/13/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228838611 |
| Principal investigator 1 | Genentech, Inc. | $3,500.00 | 05/08/2025 | Non-covered Recipient Entity UPMC OSPARS | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211679805 |
| Principal investigator 1 | PFIZER INC. | $3,075.00 | 05/05/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH CANCER | A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1228854734 |
| Principal investigator 1 | Genentech, Inc. | $248.00 | 04/28/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH CANCER INSTITUTE CANCER SERVICES | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211678925 |
| Recipient | PFIZER INC. | $780.00 | 04/25/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228838692 |
| Principal investigator 1 | Genentech, Inc. | $2,933.00 | 04/24/2025 | Non-covered Recipient Entity UPMC OSPARS | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211679803 |
| Recipient | PFIZER INC. | $3,200.00 | 04/07/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228838684 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 03/27/2025 | Non-covered Recipient Entity UPMC Hillman Cancer Center | DS8201-A-U305 | No dispute reported | 06/30/2026 | 1223386762 |
| Principal investigator 1 | Eli Lilly and Company | $3,438.00 | 03/11/2025 | Non-covered Recipient Entity UNIV OF PITTSBURGH CANCER INSTITUTE CANCER SRVCS | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187891428 |
| Principal investigator 1 | Eli Lilly and Company | $54.75 | 02/25/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF WASHINGTON MED CTR | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187875141 |
| Principal investigator 1 | Genentech, Inc. | $237.00 | 02/20/2025 | Non-covered Recipient Entity UPMC OSPARS | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211679793 |
| Principal investigator 1 | Genentech, Inc. | $1,142.00 | 02/20/2025 | Non-covered Recipient Entity UPMC OSPARS | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211679797 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,727.73 | 02/19/2025 | Non-covered Recipient Entity UPMC HILLMAN CANCER CENTER | A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole | No dispute reported | 06/30/2026 | 1185537427 |
| Principal investigator 1 | Genentech, Inc. | $1,072.00 | 02/18/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH CANCER INSTITUTE CANCER SERVICES | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211678931 |
| Principal investigator 1 | Genentech, Inc. | $375.00 | 02/13/2025 | Non-covered Recipient Entity UPMC OSPARS | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211679795 |
| Recipient | PFIZER INC. | $330.00 | 02/10/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228838120 |
| Principal investigator 1 | Genentech, Inc. | $2,550.00 | 02/07/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH CANCER INSTITUTE CANCER SERVICES | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211678923 |
| Principal investigator 1 | Genentech, Inc. | $1,250.00 | 02/07/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH CANCER INSTITUTE CANCER SERVICES | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211678927 |
| Principal investigator 1 | Genentech, Inc. | $1,965.00 | 02/07/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH CANCER INSTITUTE CANCER SERVICES | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211678929 |
| Principal investigator 1 | Genentech, Inc. | $747.00 | 01/30/2025 | Non-covered Recipient Entity UPMC OSPARS | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211679791 |
| Recipient | Novartis Pharmaceuticals Corporation | $571.31 | 01/28/2025 | Covered Recipient Physician | Research Publication/Writing Support | No dispute reported | 06/30/2026 | 1190293416 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228838700 |
| Principal investigator 1 | Eli Lilly and Company | $65.80 | 01/27/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187871285 |
| Principal investigator 1 | Eli Lilly and Company | $4,011.00 | 01/07/2025 | Covered Recipient Teaching Hospital UPMC PINNACLE HOSPITALS | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187875359 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $44,699.62 | 01/03/2025 | Non-covered Recipient Entity UPMC HILLMAN CANCER CENTER | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1185537423 |